Cancer cells have developed mechanisms to evade detection and destruction by the immune system. One such mechanism involves overexpression of the CD47 protein on cancer cell surfaces. CD47 acts as a "don't eat me" signal by binding to the SIRPα receptor on macrophages and dendritic cells, inhibiting their ability to phagocytose or engulf cells. By overexpressing CD47, cancer cells are able to cloak themselves from immune detection and clearance. Blocking the CD47-SIRPα interaction thus represents a promising strategy for enhancing anti-tumor immunity and improving outcomes for cancer patients.
Early Clinical Trials Of Anti-CD47 Drugs Antibodies
Several pharmaceutical companies have developed humanized monoclonal antibodies targeting Anti-CD47 Drugs for clinical evaluation in cancer. One of the first in clinical trials was Hu5F9-G4 or magrolimab, developed by Forty Seven Inc. Early phase I/II studies showed magrolimab to be well-tolerated and demonstrated evidence of anti-tumor activity in hematologic malignancies like acute myeloid leukemia and myelodysplastic syndromes. Other anti-CD47 antibodies entering clinical trials include ALX148 from ALX Oncology and TTI-621 from Trillium Therapeutics, both of which are being studied in patients with advanced solid tumors and hematologic cancers. Preliminary results show these drugs have reasonable safety profiles and some limited signs of efficacy as monotherapies.
Combination Therapies With Anti-CD47 Antibodies
While anti-CD47 monotherapy appears to have modest activity, blocking this key immune evasion mechanism is hypothesized to work best when combined with other immuno-oncology drugs. Several early clinical studies are exploring anti-CD47 antibodies given alongside established therapies like chemotherapy, targeted agents or checkpoint inhibitors. One notable ongoing study is combining Forty Seven's magrolimab with Merck's anti-PD-1 therapy Keytruda in patients with advanced solid tumors or lymphomas. Early results found the combination was well-tolerated with encouraging response rates seen, particularly in myeloma and lymphoma patients. Trillium is also exploring combining TTI-621 with checkpoint inhibitors in hematologic and solid tumors. These combination studies aim to leverage the synergistic effects of relieving CD47-mediated immunosuppression while also activating T cell responses with checkpoint blockade. Preliminary evidence suggests combining anti-CD47 with standard or immune-based regimens may help overcome resistance and significantly improve outcomes for certain hard-to-treat cancers.
Mode Of Action And Safety Concerns
Anti-CD47 antibodies work by blocking the interaction between cancer cell CD47 and SIRPα on macrophages and dendritic cells. This removes the "don't eat me" signal, allowing phagocytic cells to recognize tumors and destroy them. However, targeting the ubiquitous CD47 protein also carries safety risks due to its expression on normal cells. A major concern is that inhibiting CD47 could lead to depletion of red blood cells or anemia, as the protein protects healthy cells from phagocytosis. While early clinical trials found anti-CD47 antibodies were generally well-tolerated, some patients did experience mild to moderate anemia. Dose selection and scheduling are therefore critical design elements in ongoing studies. Researchers are also exploring approaches like targeting CD47 in a tissue-specific manner or selectively depleting older red blood cells to further improve the therapeutic index. Overall, clinical results to date suggest anti-CD47 therapy’s benefits outweigh the risks when dosed properly, especially when given with other cancer treatments.
Future Directions And Clinical Potential
The first generation of anti-CD47 antibodies have demonstrated acceptable safety and initial signs of efficacy against tumors in early clinical studies. But to fully realize their potential, researchers continue working to address toxicity issues, enhance combination regimens, and understand predictive biomarkers. Key ongoing areas of research include exploring additional tumor types, optimizing dosing schedules, identifying patient populations most likely to respond, and conducting robust combination studies.
If Found To Synergize Strongly With Immune Checkpoint Or Conventional Cancer Therapies, Anti-CD47 antibodies may become important new first- or second-line treatment options across both hematologic and solid tumors. With further development and refinement, blocking the CD47-SIRPα axis holds tremendous promise to significantly improve clinical outcomes for many cancer patients by empowering immune cells to attack tumors.
Get more insights on this topic: https://www.dailyprbulletin.com/anti-cd47-drugs-a-new-hope-in-cancer-treatment-the-emergence-of-promising-therapeutic-class/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it